Skip to main content

Citius Pharmaceuticals, Inc.

corporate_fare Company Profile

Citius Pharmaceuticals, Inc.

CTXR·NASDAQ·Life Sciences·CIK 0001506251

Citius Pharmaceuticals, Inc., based in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing critical care products, particularly in oncology, anti-infectives for adjunct cancer care, and unique prescription products. The company aims for leading market positions by offering therapeutic products that address unmet medical needs with lower development risk, often by reformulating previously approved drugs with existing safety and efficacy data. This strategy focuses on products with intellectual property and regulatory exclusivity. In December 2025, Citius Pharmaceuticals became a commercial company with the launch of LYMPHIR by its majority-owned subsidiary, Citius Oncology. LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, received FDA approval for treating patients with persistent or recurrent cutaneous T-cell lymphoma ("CTCL"). Citius Pharma in-licensed LYMPHIR in September 2021, and it is now owned by Citius Oncology. The company is also developing three proprietary products: Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation for hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for ARDS. Since its inception, the company has focused on business planning, acquiring technology, research and development, staffing, and raising capital.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CTXR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 19 rated 8 or above. Recent SEC coverage for CTXR spans 8-K, 10-Q, S-3, 424B5.

Recent high-impact activity:

  • Citius Oncology Q4 LYMPHIR Wholesaler Units Jump 120% to 792
  • Citius Pharma Gets Nasdaq Extension to Feb 8, 2027 to Regain $1 Bid Compliance
  • Citius Pharma Q3 10-Q: $49.4M Loss, Cash Runway to November, Going Concern
  • Citius Pharma Posts $7.1M LYMPHIR Revenue, 383 Vial Orders in July
  • Citius Oncology Reports 78% QoQ Growth in New Institutions Ordering LYMPHIR

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$39.74M
Diluted EPS
-$3.38
Op. Cash Flow
-$26.55M
Operating Income
-$38.53M
Cash & Equivalents
$4.25M
Debt / Equity
0.00×
Shares Outstanding
18.07M sh
Source: 10-K · filed 2026-01-28 · accession 0001213900-26-008861

Short Interest & Short Volume

17.76 days to cover

FINRA reported short interest of 5,764,914 shares in CTXR as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 17.8 days to cover at its recent average daily volume. On November 20, 2026, 64.1% of CTXR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,764,914 shares as of October 30, 2026
Change vs prior period▲ 1.2%
Days to cover17.76 at avg daily volume of 324,581
Daily short volume (FINRA facilities)64.1% of 155,382 shares on November 20, 2026
5-day average short volume52.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$0.5085
52-week range · as of 2026-10-26 $0.3699 – $1.98
Market cap
$13.96M
Volume
183.7K (0.7× avg)
3-mo avg 263.4K
Live data · 2026-11-22 12:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CTXR - Latest Insights

CTXR
Oct 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4493
Real-time Price: $0.5085 info
Change: +$0.0592 (+13%) info
Market Cap: $13.96M info
CTXR
Aug 21, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6002
Real-time Price: $0.5085 info
Change: -$0.0917 (-15%) info
Market Cap: $13.96M info
CTXR
Aug 14, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.750
Real-time Price: $0.5085 info
Change: -$0.2415 (-32%) info
Market Cap: $13.96M info
CTXR
Aug 14, 2026, 4:30 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $0.7556
Real-time Price: $0.5085 info
Change: -$0.2471 (-33%) info
Market Cap: $13.96M info
CTXR
Aug 05, 2026, 9:27 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6439
Real-time Price: $0.5085 info
Change: -$0.1354 (-21%) info
Market Cap: $13.96M info
CTXR
Jun 01, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.634
Real-time Price: $0.5085 info
Change: -$0.1255 (-20%) info
Market Cap: $13.96M info
CTXR
Jun 01, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.634
Real-time Price: $0.5085 info
Change: -$0.1255 (-20%) info
Market Cap: $13.96M info
CTXR
May 22, 2026, 5:00 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.6811
Real-time Price: $0.5085 info
Change: -$0.1726 (-25%) info
Market Cap: $13.96M info
CTXR
May 16, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.610
Real-time Price: $0.5085 info
Change: -$0.1015 (-17%) info
Market Cap: $13.96M info
CTXR
May 15, 2026, 4:41 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6937
Real-time Price: $0.5085 info
Change: -$0.1852 (-27%) info
Market Cap: $13.96M info
CTXR
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.6937
Real-time Price: $0.5085 info
Change: -$0.1852 (-27%) info
Market Cap: $13.96M info
CTXR
May 15, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7213
Real-time Price: $0.5085 info
Change: -$0.2128 (-30%) info
Market Cap: $13.96M info
CTXR
May 08, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6465
Real-time Price: $0.5085 info
Change: -$0.138 (-21%) info
Market Cap: $13.96M info
CTXR
Apr 24, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7481
Real-time Price: $0.5085 info
Change: -$0.2396 (-32%) info
Market Cap: $13.96M info
CTXR
Apr 24, 2026, 9:24 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.7898
Real-time Price: $0.5085 info
Change: -$0.2813 (-36%) info
Market Cap: $13.96M info
CTXR
Mar 31, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.9159
Real-time Price: $0.5085 info
Change: -$0.4074 (-44%) info
Market Cap: $13.96M info
CTXR
Mar 31, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.9263
Real-time Price: $0.5085 info
Change: -$0.4178 (-45%) info
Market Cap: $13.96M info
CTXR
Mar 10, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.853
Real-time Price: $0.5085 info
Change: -$0.3445 (-40%) info
Market Cap: $13.96M info
CTXR
Mar 04, 2026, 9:25 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.770
Real-time Price: $0.5085 info
Change: -$0.2615 (-34%) info
Market Cap: $13.96M info
CTXR
Feb 24, 2026, 8:00 AM EST
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.6655
Real-time Price: $0.5085 info
Change: -$0.157 (-24%) info
Market Cap: $13.96M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets